Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Myelodysplastic Syndromes 5Leukemia, Myeloid, Acute 3Leukemia 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Stomach Neoplasms 1Rubinstein-Taybi Syndrome 1Prostatic Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Carcinoma, Transitional Cell 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × mocetinostat × Clear all
NCT00358982 2015-07-03

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Mirati Therapeutics Inc.

Phase 2 Terminated
51 enrolled
Lymphoid

Hodgkin Disease, Recurrence

NCT00359086 2015-07-01

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Mirati Therapeutics Inc.

Phase 2 Completed
74 enrolled
Lymphoid

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡